{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:06:41Z","timestamp":1773356801627,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82570240"],"award-info":[{"award-number":["82570240"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82200887"],"award-info":[{"award-number":["82200887"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370194"],"award-info":[{"award-number":["82370194"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023M741463"],"award-info":[{"award-number":["2023M741463"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2022M7114034"],"award-info":[{"award-number":["2022M7114034"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008868","name":"Jiangsu Science and Technology Department","doi-asserted-by":"crossref","award":["BK20220716"],"award-info":[{"award-number":["BK20220716"]}],"id":[{"id":"10.13039\/501100008868","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nanjing Municipal Returned Overseas Scholars Foundation","award":["BSHNJ2023011"],"award-info":[{"award-number":["BSHNJ2023011"]}]},{"name":"Jiangsu Province Hospital Talent Specialized Foundation","award":["MXJL202107"],"award-info":[{"award-number":["MXJL202107"]}]},{"name":"Jiangsu Province \"333\" Project","award":["BRA2018085"],"award-info":[{"award-number":["BRA2018085"]}]},{"name":"Jiangsu Province Hospital Clinical Diagnosis and Treatment Technologies Innovation Project Foundation","award":["JBGS202405"],"award-info":[{"award-number":["JBGS202405"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04679-1","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T01:34:06Z","timestamp":1770600846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Jin-Hua","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong-Yao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Shu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luthuli","family":"Sibusiso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Zhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Rui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"issue":"11","key":"4679_CR1","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/ajh.27075","volume":"98","author":"M Tavakkoli","year":"2023","unstructured":"Tavakkoli M, Barta SK. 2024 update: advances in the risk stratification and management of large B-cell lymphoma. Am J Hematol. 2023;98(11):1791\u2013805. https:\/\/doi.org\/10.1002\/ajh.27075.","journal-title":"Am J Hematol"},{"key":"4679_CR2","doi-asserted-by":"publisher","unstructured":"Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737\u20132746. Blood. 2023;141(6):683.\nhttps:\/\/doi.org\/10.1182\/blood.2022018793.","DOI":"10.1182\/blood.2022018793"},{"issue":"1","key":"4679_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w","volume":"14","author":"A Trabolsi","year":"2024","unstructured":"Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024;14(1):27. https:\/\/doi.org\/10.1038\/s41408-024-00997-w.","journal-title":"Blood Cancer J"},{"issue":"4","key":"4679_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.27630","volume":"100","author":"S Yamshon","year":"2025","unstructured":"Yamshon S, Koff JL, Larson MC, et al. Outcomes of relapsed or refractory diffuse large B-cell lymphoma treated with R-GemOx: a multicenter cohort study. Am J Hematol. 2025;100(4):606\u201315. https:\/\/doi.org\/10.1002\/ajh.27630.","journal-title":"Am J Hematol"},{"issue":"5","key":"4679_CR5","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.clml.2024.01.010","volume":"24","author":"M Garg","year":"2024","unstructured":"Garg M, Puckett J, Kamal-Bahl S, et al. Real-world survival, healthcare resource utilization, and costs among U.S. elderly patients with diffuse large B-cell lymphoma (DLBCL) treated with R-GemOx in the relapsed\/refractory setting. Clin Lymphoma Myeloma Leuk. 2024;24(5):e181\u201390. https:\/\/doi.org\/10.1016\/j.clml.2024.01.010.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"4679_CR6","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1080\/10428194.2021.1901090","volume":"62","author":"C Cazelles","year":"2021","unstructured":"Cazelles C, Belhadj K, Vellemans H, et al. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory\/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leuk Lymphoma. 2021;62(9):2161\u20138. https:\/\/doi.org\/10.1080\/10428194.2021.1901090.","journal-title":"Leuk Lymphoma"},{"issue":"10466","key":"4679_CR7","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/s0140-6736(24)01774-4","volume":"404","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024;404(10466):1940\u201354. https:\/\/doi.org\/10.1016\/s0140-6736(24)01774-4.","journal-title":"Lancet"},{"issue":"17","key":"4679_CR8","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1158\/1078-0432.Ccr-24-0183","volume":"30","author":"B Rey-B\u00faa","year":"2024","unstructured":"Rey-B\u00faa B, Grande C, S\u00e1nchez Blanco JJ, et al. Ibrutinib in combination with R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma of nongerminal center B-cell-like type: phase II clinical trial of the Spanish GELTAMO group. Clin Cancer Res. 2024;30(17):3704\u201314. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-0183.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4679_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/jco.18.00766","volume":"37","author":"SM Ansell","year":"2019","unstructured":"Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37(6):481\u20139. https:\/\/doi.org\/10.1200\/jco.18.00766.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4679_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/bjh.18775","volume":"202","author":"N Gazeau","year":"2023","unstructured":"Gazeau N, Mitra S, Nudel M, et al. Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma. Br J Haematol. 2023;202(2):434\u20136. https:\/\/doi.org\/10.1111\/bjh.18775.","journal-title":"Br J Haematol"},{"key":"4679_CR11","doi-asserted-by":"publisher","unstructured":"Ho C, Gopal AK, Till BG, et al. Pembrolizumab with R-CHOP in previously untreated DLBCL: sustained, high efficacy, and safety with long-term follow-up. Clin Lymphoma Myeloma Leuk. 2024;24(2):e33-e9.e1.\nhttps:\/\/doi.org\/10.1016\/j.clml.2023.10.002.","DOI":"10.1016\/j.clml.2023.10.002"},{"issue":"6","key":"4679_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/bjh.16494","volume":"189","author":"SD Smith","year":"2020","unstructured":"Smith SD, Till BG, Shadman MS, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020;189(6):1119\u201326. https:\/\/doi.org\/10.1111\/bjh.16494.","journal-title":"Br J Haematol"},{"issue":"1","key":"4679_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/bloodadvances.2019000784","volume":"4","author":"MJ Frigault","year":"2020","unstructured":"Frigault MJ, Armand P, Redd RA, et al. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020;4(1):122\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2019000784.","journal-title":"Blood Adv"},{"issue":"3","key":"4679_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/ejh.14013","volume":"111","author":"Y Qin","year":"2023","unstructured":"Qin Y, He X, Chen X, et al. Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed\/refractory diffuse large B cell lymphoma patients. Eur J Haematol. 2023;111(3):356\u201364. https:\/\/doi.org\/10.1111\/ejh.14013.","journal-title":"Eur J Haematol"},{"issue":"18","key":"4679_CR15","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s40265-021-01640-9","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Penpulimab: first approval. Drugs. 2021;81(18):2159\u201366. https:\/\/doi.org\/10.1007\/s40265-021-01640-9.","journal-title":"Drugs"},{"key":"4679_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.925236","volume":"12","author":"Y Song","year":"2022","unstructured":"Song Y, Zhou K, Jin C, et al. Penpulimab for relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, pivotal phase I\/II trial (AK105-201). Front Oncol. 2022;12:925236. https:\/\/doi.org\/10.3389\/fonc.2022.925236.","journal-title":"Front Oncol"},{"issue":"22","key":"4679_CR17","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1200\/jco.2017.72.6984","volume":"35","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, Tilly H, da Gomes Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35(22):2473\u201381. https:\/\/doi.org\/10.1200\/jco.2017.72.6984.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4679_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/jco.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: A phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317\u201328. https:\/\/doi.org\/10.1200\/jco.20.01366.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4679_CR19","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/jco.20.01375","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol. 2021;39(12):1329\u201338. https:\/\/doi.org\/10.1200\/jco.20.01375.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4679_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1634\/theoncologist.2016-0103","volume":"21","author":"P Mondello","year":"2016","unstructured":"Mondello P, Steiner N, Willenbacher W, et al. Lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: is it a valid treatment option? Oncologist. 2016;21(9):1107\u201312. https:\/\/doi.org\/10.1634\/theoncologist.2016-0103.","journal-title":"Oncologist"},{"issue":"10","key":"4679_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","volume":"130","author":"A Badros","year":"2017","unstructured":"Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma. Blood. 2017;130(10):1189\u201397. https:\/\/doi.org\/10.1182\/blood-2017-03-775122.","journal-title":"Blood"},{"issue":"14","key":"4679_CR22","doi-asserted-by":"publisher","first-page":"24031","DOI":"10.18632\/oncotarget.15234","volume":"8","author":"M Giuliani","year":"2017","unstructured":"Giuliani M, Janji B, Berchem G. Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget. 2017;8(14):24031\u201344. https:\/\/doi.org\/10.18632\/oncotarget.15234.","journal-title":"Oncotarget"},{"issue":"1","key":"4679_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","volume":"62","author":"K Luptakova","year":"2013","unstructured":"Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013;62(1):39\u201349. https:\/\/doi.org\/10.1007\/s00262-012-1308-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"4679_CR24","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/bjh.16211","volume":"187","author":"C Di Raimondo","year":"2019","unstructured":"Di Raimondo C, Abdulla FR, Zain J, et al. Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol. 2019;187(3):e79\u201382. https:\/\/doi.org\/10.1111\/bjh.16211.","journal-title":"Br J Haematol"},{"issue":"20","key":"4679_CR25","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.Ccr-15-0200","volume":"21","author":"G G\u00f6rg\u00fcn","year":"2015","unstructured":"G\u00f6rg\u00fcn G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21(20):4607\u201318. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0200.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4679_CR26","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41375-024-02279-7","volume":"38","author":"JH Liang","year":"2024","unstructured":"Liang JH, Wu YF, Shen HR, et al. Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma. Leukemia. 2024;38(7):1541\u201352. https:\/\/doi.org\/10.1038\/s41375-024-02279-7.","journal-title":"Leukemia"},{"issue":"4","key":"4679_CR27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551-68.e14. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015.","journal-title":"Cancer Cell"},{"issue":"16","key":"4679_CR28","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","volume":"131","author":"F Vari","year":"2018","unstructured":"Vari F, Arpon D, Keane C, et al. Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018;131(16):1809\u201319. https:\/\/doi.org\/10.1182\/blood-2017-07-796342.","journal-title":"Blood"},{"issue":"2","key":"4679_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","volume":"44","author":"C Pfirschke","year":"2016","unstructured":"Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44(2):343\u201354. https:\/\/doi.org\/10.1016\/j.immuni.2015.11.024.","journal-title":"Immunity"},{"issue":"6","key":"4679_CR30","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012.","journal-title":"Cancer Cell"},{"issue":"6332","key":"4679_CR31","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Wieland A, Nasti T, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355(6332):1423\u20137. https:\/\/doi.org\/10.1126\/science.aaf0683.","journal-title":"Science"},{"issue":"8","key":"4679_CR32","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.chembiol.2022.05.012","volume":"29","author":"CL Geng","year":"2022","unstructured":"Geng CL, Chen JY, Song TY, et al. Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling. Cell Chem Biol. 2022;29(8):1260-72.e8. https:\/\/doi.org\/10.1016\/j.chembiol.2022.05.012.","journal-title":"Cell Chem Biol"},{"key":"4679_CR33","doi-asserted-by":"publisher","unstructured":"Han Z, Wu X, Qin H, et al. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma. JCI Insight. 2023;8(13). https:\/\/doi.org\/10.1172\/jci.insight.163518.","DOI":"10.1172\/jci.insight.163518"},{"key":"4679_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1632039","volume":"15","author":"H Dong","year":"2025","unstructured":"Dong H, Wang R, Cheng L, et al. Treatment of relapsed or refractory Hodgkin\u2019s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review. Front Oncol. 2025;15:1632039. https:\/\/doi.org\/10.3389\/fonc.2025.1632039.","journal-title":"Front Oncol"},{"key":"4679_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1629224","volume":"16","author":"L Wang","year":"2025","unstructured":"Wang L, Huang Y, Xu D, et al. Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed\/refractory diffuse large B-cell lymphoma. Front Immunol. 2025;16:1629224. https:\/\/doi.org\/10.3389\/fimmu.2025.1629224.","journal-title":"Front Immunol"},{"issue":"2","key":"4679_CR36","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.21037\/tcr-23-1638","volume":"13","author":"X Chen","year":"2024","unstructured":"Chen X, Zhang Z, Zhang J, et al. Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5(+) diffuse large B-cell lymphoma with MYD88 and CD79B comutation: a case report. Transl Cancer Res. 2024;13(2):1188\u201395. https:\/\/doi.org\/10.21037\/tcr-23-1638.","journal-title":"Transl Cancer Res"},{"key":"4679_CR37","doi-asserted-by":"publisher","unstructured":"Held G, Altmann B, Kerkhoff A, et al. R-GemOx plus nivolumab vs R-GemOx as second-line therapy for large B-cell lymphoma in transplant-ineligible patients: interim analysis of the Niveau Trial, an International, randomized phase 3 study of the AGMT, GLA, HOVON, Lysa and PLRG. Blood. 2023;142(Supplement 1):435-.\nhttps:\/\/doi.org\/10.1182\/blood-2023-172951.","DOI":"10.1182\/blood-2023-172951"},{"issue":"9","key":"4679_CR38","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/leu.2013.95","volume":"27","author":"M Wang","year":"2013","unstructured":"Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27(9):1902\u20139. https:\/\/doi.org\/10.1038\/leu.2013.95.","journal-title":"Leukemia"},{"issue":"11","key":"4679_CR39","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","volume":"98","author":"N Mounier","year":"2013","unstructured":"Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013;98(11):1726\u201331. https:\/\/doi.org\/10.3324\/haematol.2013.090597.","journal-title":"Haematologica"},{"issue":"12","key":"4679_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03840-0","volume":"73","author":"X Chen","year":"2024","unstructured":"Chen X, Qin Y, Xue X, et al. Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed\/refractory diffuse large B-cell lymphoma. Cancer Immunol Immunother. 2024;73(12):250. https:\/\/doi.org\/10.1007\/s00262-024-03840-0.","journal-title":"Cancer Immunol Immunother"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04679-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:34Z","timestamp":1773318694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04679-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4679"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04679-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and\u00a0the study protocol was approved by the Ethics Committee of the Institutional\u00a0Review Broad of Jiangsu Province Hospital (No. 2021-SR-545) and informed\u00a0consent was retrieved from subjects involved in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}